Dr. Julia Bohlius and Dr. Andreas Engert discuss findings that cancer patients on erythropoiesis-stimulating agents are 17% more likely to die of any cause while in clinical trials. Jane MacNeil of Elsevier Global Medical News (EGMN) reports from the annual meeting of the American Society of Hematology.